Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Total Articles

7
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (0)

Searched Name

Tenormin

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	Drugs for hypertension. THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS 2024;66:81-88. [PMID: 38771738 DOI: 10.58347/tml.2024.1703a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2024] Abstract American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018.1 Treatment of hypertensive urgencies and emergencies is not discussed here. Collapse Key Words ACE inhibitors ARBs Accupril Accuretic Aldactone Altace Atacand Avalide Avapro Azor Benicar Bystolic Cardizem Cardura CaroSpir Cartia Corgard Cozaar Dilt-XR Diovan Diuril Dyrenium Edarbi Edarbyclor Edecrin Epaned Exforge Hyzaar Inderal InnoPran Inspra Kapspargo Sprinkle Katerzia Lasix Lopressor Lotensin Lotrel Matzim Micardis Norvasc Prestalia Procardia Qbrelis Soaanz Sular Taztia Tekturna Tenoretic Tenormin Thalitone Tiadylt Tiazac Toprol Tribenzor Tryvio Vaseretic Vasotec Verelan Zestoretic Zestril acebutolol adverse effects aliskiren amiloride amlodipine aprocitentan atenolol azilsartan benazepril beta blockers betaxolol bisoprolol bumetanide candesartan captopril carvedilol chlorothiazide chlorthalidone clonidine diltiazem diuretics dosage doxazosin efficacy enalapril eplerenone eprosartan ethacrynic acid felodipine fosinopril furosemide guanfacine hydralazine hydrochlorothiazide hypertension indapamide irbesartan isradipine labetalol lisinopril losartan methyldopa metolazone metoprolol minoxidil moexipril nadolol nebivolol nicardipine nifedipine nisoldipine olmesartan perindopril pindolol prazosin pregnancy propranolol quinapril ramipril safety spironolactone telmisartan terazosin timolol torsemide trandolapril triamterene valsartan verapamil Collapse MESH Headings Humans Hypertension/drug therapy Hypertension/physiopathology Antihypertensive Agents/therapeutic use Antihypertensive Agents/adverse effects Antihypertensive Agents/administration & dosage Blood Pressure/drug effects Collapse Grants Collapse
2	Treatment of atrial fibrillation. THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS 2024;66:1-8. [PMID: 38180321 DOI: 10.58347/tml.2024.1693a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2024] Abstract Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently. Collapse Key Words Andexxa Betapace Brevibloc Cardizem Cartia Coreg Corgard DOAC Eliquis Inderal InnoPran Jantoven Kapspargo Sprinkle Lanoxin Lopressor Mephyton Multaq Norpace Pacerone Plavix Pradaxa Praxbind Rythmol Savaysa Taztia Tenormin Tiazac Tikosyn Toprol Verelan Xarelto adverse effects amiodarone andexanet alfa anticoagulants apixaban atenolol atrial fibrillation beta blockers bisoprolol carvedilol catheter ablation clopidogrel dabigatran digoxin diltiazem disopyramide dofetilide dosage dronedarone drug interactions edoxaban efficacy esmolol flecainide ibutilide idarucizumab metoprolol nadolol propafenone propranolol rivaroxaban safety sotalol verapamil vitamin K warfarin Collapse MESH Headings Humans Atrial Fibrillation/diagnosis Atrial Fibrillation/drug therapy Collapse Grants Collapse
3	Eptinezumab (Vyepti) for migraine prevention. THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS 2020;62:85-87. [PMID: 32555116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023] Abstract Collapse Key Words Aimovig Ajovy Atacand Botox Corgard Cymbalta Depakote Effexor Emgality Epival Inderal Lopressor SNRIs Tenormin Topamax Vyepti Ziac adverse effects amitriptyline atenolol beta blockers bisoprolol candesartan dosage duloxetine efficacy eptinezumab erenumab fremanezumab galcanezumab lactation metoprolol migraine nadolol onabotulinumtoxinA pregnancy propranolol safety timolol topiramate tricyclic antidepressants venlafaxine Collapse MESH Headings Antibodies, Monoclonal, Humanized/administration & dosage Antibodies, Monoclonal, Humanized/adverse effects Antibodies, Monoclonal, Humanized/pharmacology Calcitonin Gene-Related Peptide Receptor Antagonists/administration & dosage Calcitonin Gene-Related Peptide Receptor Antagonists/adverse effects Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacology Humans Migraine Disorders/physiopathology Migraine Disorders/prevention & control Collapse Grants Collapse
4	Drugs for hypertension. THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS 2020;62:73-80. [PMID: 32555118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023] Abstract Collapse Key Words ACE inhibitors ARBs Accupril Accuretic Adalat Aldactone Altace Atacand Avalide Avapro Benicar Bystolic Calan Cardizem Cardura CaroSpir Cartia Catapres Coreg Corgard Cozaar Dilt-XR Diovan Diuril Dutoprol Dyrenium Edarbi Edarbyclor Edecrin Epaned Hyzaar Inderal InnoPran Inspra Kapspargo Sprinkle Katerzia Lasix Lopressor Lotensin Matzim Micardis Minipress Norvasc Prinivil Procardia Qbrelis Sular Taztia Tekturna Tenoretic Tenormin Tiadylt Tiazac Toprol Vaseretic Vasotec Verelan Zestoretic Zestril Ziac acebutolol adverse effects aliskiren amiloride amlodipine atenolol azilsartan benazapril beta blockers betaxolol bisoprolol bumetanide calcium-channel blockers candesartan captopril carvedilol chlorthalidone clonidine diltiazem diuretics dosage doxazosin efficacy enalapril eplerenone eprosartan ethacrynic acid felodipine fosinopril furosemide guanfacine hydralazine hydrochlorothiazide hypertension indapamide irbesartan isradipine labetalol lisinopril losartan methyldopa metolazone metoprolol minoxidil moexipril nadolol nebivolol nicardipine nifedipine nisoldipine olmesartan perindopril pindolol prazosin pregnancy propranolol quinapril ramipril safety spironolactone telmisartan terazosin timolol torsemide trandolapril triamterene valsartan verapamil Collapse MESH Headings Antihypertensive Agents/adverse effects Antihypertensive Agents/pharmacology Antihypertensive Agents/therapeutic use Blood Pressure/drug effects Humans Hypertension/drug therapy Hypertension/physiopathology Collapse Grants Collapse
5	Drugs for atrial fibrillation. THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS 2019;61:137-144. [PMID: 31599871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023] Abstract Collapse Key Words Antiarrythmic Drugs Beta-adrenergic blockers Betapace Brevibloc Calan Cardizem Cartia Catheter Ablation Coreg Corgard Coumadin DOAC Digitek Digox Eliquis Inderal InnoPran Isoptin Kapspargo Sprinkle Lanoxin Lixiana Lopressor Mephyton Multaq NOAC Norpace Pacerone Pradaxa Praxbind Rate Control Rhythm Control Rythmol Savaysa Sotalol Taztia Tenormin Tiazac Tikosyn Toprol Verelan Xarelto adverse effects amiodarone andexanet alfa anticoagulants apixaban atenolol atrial fibrillation beta blockers bisoprolol calcium-channel blockers carvedilol dabigatran digoxin diltiazem disopyramide dofetilide dosage dronedarone drug interactions edoxaban efficacy esmolol flecainide idarucizumab metoprolol nadolol propafenone propranolol rivaroxaban safety sotalol verapamil vitamin K warfarin weight loss Collapse MESH Headings Adrenergic beta-Antagonists/pharmacokinetics Adrenergic beta-Antagonists/therapeutic use Animals Anti-Arrhythmia Agents/pharmacokinetics Anti-Arrhythmia Agents/therapeutic use Anticoagulants/pharmacokinetics Anticoagulants/therapeutic use Atrial Fibrillation/drug therapy Atrial Fibrillation/epidemiology Atrial Fibrillation/metabolism Calcium Channel Blockers/pharmacokinetics Calcium Channel Blockers/therapeutic use Clinical Trials as Topic/methods Dabigatran/pharmacokinetics Dabigatran/therapeutic use Humans Rivaroxaban/pharmacokinetics Rivaroxaban/therapeutic use Collapse Grants Collapse
6	Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention. THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS 2018;60:177-180. [PMID: 30681655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Abstract Collapse Key Words Aimovig Ajovy Botox Corgard Cymbalta Depakote Effexor Emgality Epival Inderal Lopressor Qudexy SNRIs Tenormin Topamax Trokendi adverse effects amitriptyline antidepressants atenolol beta blockers botulinum toxin dosage duloxetine efficacy erenumab fremanezumab galcanezumab metoprolol migraine nadolol onabotulinumtoxinA pregnancy propranolol safety timolol topiramate tricyclic antidepressants valproate venlafaxine Collapse MESH Headings Analgesics/administration & dosage Analgesics/adverse effects Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal/adverse effects Antibodies, Monoclonal, Humanized Calcitonin Gene-Related Peptide/antagonists & inhibitors Calcitonin Gene-Related Peptide/immunology Calcitonin Gene-Related Peptide/metabolism Humans Injections, Subcutaneous Migraine Disorders/diagnosis Migraine Disorders/immunology Migraine Disorders/metabolism Migraine Disorders/prevention & control Signal Transduction/drug effects Treatment Outcome Collapse Grants Collapse
7	Erenumab (Aimovig) for migraine prevention. THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS 2018;60:101-103. [PMID: 29913472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023] Abstract Collapse Key Words Aimovig Botox Corgard Cymbalta Depakote Effexor Epival Inderal Lixiana Lopresor Lopressor Qudexy SNRIs Tenormin Topamax Trokendi adverse effects amitriptyline antiepileptics atenolol beta blockers botulinum toxin dosage duloxetine efficacy erenumab metoprolol migraine nadolol onabotulinumtoxinA pregnancy propranolol safety timolol topiramate tricyclic antidepressants valproate venlafaxine Collapse MESH Headings Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal/pharmacology Antibodies, Monoclonal, Humanized Calcitonin Gene-Related Peptide/antagonists & inhibitors Drug Approval Humans Injections, Subcutaneous Migraine Disorders/prevention & control Randomized Controlled Trials as Topic United States United States Food and Drug Administration Collapse Grants Collapse